Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunomedics Inc. IMMU

Immunomedics Inc is a clinical-stage biopharmaceutical company, based in the United States. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others. Its portfolio of products under investigation include antibody-drug conjugates that target the tumor-reducing toxic effects of chemotherapeutic treatments. The company's pipeline includes products targeting solid tumors and hematologic malignancies, among other diseases in c


NDAQ:IMMU - Post by User

Bullboard Posts
Next >>
Post by Ferrelon Feb 07, 2014 10:17pm
205 Views
Post# 22186698

regarding innexus dynamic cross linking technology

regarding innexus dynamic cross linking technologyyou guys are using.
can you inbox me please, i have a boat load of shares in that stock and would like to have any information you can give me.
ixs.h  and ixsbf on pinks.
since our ceo died in a plane crash back in 2010 our company went blackout.
we have numerous collaborators ,and i finally found you guys through one of your patents
using our technology.
anything you can offer i will pass over to the shareholders of ixs.h bullboard as we have not seen any news in years and have no idea what is going on.
thank you very very much in advance.

(I a 2nd-generation humanized anti-CD20 antibody of Immunomedics or DXL625,mmunomedics) which are comprised of a divalent anti-CD20 IgG of veltuzumab and a pair of stabilized dimers of Fab derived from milatuzumab, an anti-CD20 mAb enhanced with InNexus' Dynamic Cross Linking technology, of Inexus Biotechnology both are humanized anti-CD20 antibodies are suitable.

Bullboard Posts
Next >>